Plus, news about Anavex, Alnylam, Rapport Therapeutics, Dianthus Therapeutics, Ultragenyx, Atom Therapeutics, Alchemab, BioMarin, Amgen, Kyowa Kirin and Bristol Myers Squibb:
🤧 Regeneron’s allergy drugs clear Phase 3 trials: The company’s allergen-blocking antibody candidates ...
↧